Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle

Antonella Amato, Sara Baldassano, Rosa Liotta, Rosa Serio, Flavia Mulè

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Glucagon-like peptide 1 (GLP1) is a naturally occurring peptide secreted by intestinal L-cells. Though its primary function is to serve as an incretin, GLP1 reduces gastrointestinal motility. However, only a handful of animal studies have specifically evaluated the influence of GLP1 on colonic motility. Consequently, the aims of this study were to investigate the effects induced by exogenous GLP1, to analyze the mechanism of action, and to verify the presence of GLP1 receptors (GLP1Rs) in human colon circular muscular strips. Organ bath technique, RT-PCR, western blotting, and immunofluorescence were used. In human colon, exogenous GLP1 reduced, in a concentration-dependent manner, the amplitude of the spontaneous contractions without affecting the frequency and the resting basal tone. This inhibitory effect was significantly reduced by exendin (9-39), a GLP1R antagonist, which per se significantly increased the spontaneous mechanical activity. Moreover, it was abolished by tetrodotoxin, a neural blocker, or Nω-nitro-L-arginine - a blocker of neuronal nitric oxide synthase (nNOS). The biomolecular analysis revealed a genic and protein expression of the GLP1R in the human colon. The double-labeling experiments with anti-neurofilament or anti-nNOS showed, for the first time, that immunoreactivity for the GLP1R was expressed in nitrergic neurons of the myenteric plexus. In conclusion, the results of this study suggest that GLP1R is expressed in the human colon and, once activated by exogenous GLP1, mediates an inhibitory effect on large intestine motility through NO neural release.

Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalJournal of Endocrinology
Volume221
Issue number1
DOIs
Publication statusPublished - Apr 2014

Fingerprint

Glucagon-Like Peptide 1
Colon
Muscles
Nitric Oxide Synthase Type I
Nitrergic Neurons
Enteroendocrine Cells
Incretins
Myenteric Plexus
Gastrointestinal Motility
Intermediate Filaments
Large Intestine
Tetrodotoxin
Baths
Fluorescent Antibody Technique
Arginine
Western Blotting
Polymerase Chain Reaction
Peptides
Proteins

Keywords

  • Colonic motility
  • GLP-1 receptor expression
  • Intestinal peptides
  • Nitric oxide

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. / Amato, Antonella; Baldassano, Sara; Liotta, Rosa; Serio, Rosa; Mulè, Flavia.

In: Journal of Endocrinology, Vol. 221, No. 1, 04.2014, p. 29-37.

Research output: Contribution to journalArticle

Amato, Antonella ; Baldassano, Sara ; Liotta, Rosa ; Serio, Rosa ; Mulè, Flavia. / Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. In: Journal of Endocrinology. 2014 ; Vol. 221, No. 1. pp. 29-37.
@article{12eba5f31c69465a8cfdddc38e332f5b,
title = "Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle",
abstract = "Glucagon-like peptide 1 (GLP1) is a naturally occurring peptide secreted by intestinal L-cells. Though its primary function is to serve as an incretin, GLP1 reduces gastrointestinal motility. However, only a handful of animal studies have specifically evaluated the influence of GLP1 on colonic motility. Consequently, the aims of this study were to investigate the effects induced by exogenous GLP1, to analyze the mechanism of action, and to verify the presence of GLP1 receptors (GLP1Rs) in human colon circular muscular strips. Organ bath technique, RT-PCR, western blotting, and immunofluorescence were used. In human colon, exogenous GLP1 reduced, in a concentration-dependent manner, the amplitude of the spontaneous contractions without affecting the frequency and the resting basal tone. This inhibitory effect was significantly reduced by exendin (9-39), a GLP1R antagonist, which per se significantly increased the spontaneous mechanical activity. Moreover, it was abolished by tetrodotoxin, a neural blocker, or Nω-nitro-L-arginine - a blocker of neuronal nitric oxide synthase (nNOS). The biomolecular analysis revealed a genic and protein expression of the GLP1R in the human colon. The double-labeling experiments with anti-neurofilament or anti-nNOS showed, for the first time, that immunoreactivity for the GLP1R was expressed in nitrergic neurons of the myenteric plexus. In conclusion, the results of this study suggest that GLP1R is expressed in the human colon and, once activated by exogenous GLP1, mediates an inhibitory effect on large intestine motility through NO neural release.",
keywords = "Colonic motility, GLP-1 receptor expression, Intestinal peptides, Nitric oxide",
author = "Antonella Amato and Sara Baldassano and Rosa Liotta and Rosa Serio and Flavia Mul{\`e}",
year = "2014",
month = "4",
doi = "10.1530/JOE-13-0525",
language = "English",
volume = "221",
pages = "29--37",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle

AU - Amato, Antonella

AU - Baldassano, Sara

AU - Liotta, Rosa

AU - Serio, Rosa

AU - Mulè, Flavia

PY - 2014/4

Y1 - 2014/4

N2 - Glucagon-like peptide 1 (GLP1) is a naturally occurring peptide secreted by intestinal L-cells. Though its primary function is to serve as an incretin, GLP1 reduces gastrointestinal motility. However, only a handful of animal studies have specifically evaluated the influence of GLP1 on colonic motility. Consequently, the aims of this study were to investigate the effects induced by exogenous GLP1, to analyze the mechanism of action, and to verify the presence of GLP1 receptors (GLP1Rs) in human colon circular muscular strips. Organ bath technique, RT-PCR, western blotting, and immunofluorescence were used. In human colon, exogenous GLP1 reduced, in a concentration-dependent manner, the amplitude of the spontaneous contractions without affecting the frequency and the resting basal tone. This inhibitory effect was significantly reduced by exendin (9-39), a GLP1R antagonist, which per se significantly increased the spontaneous mechanical activity. Moreover, it was abolished by tetrodotoxin, a neural blocker, or Nω-nitro-L-arginine - a blocker of neuronal nitric oxide synthase (nNOS). The biomolecular analysis revealed a genic and protein expression of the GLP1R in the human colon. The double-labeling experiments with anti-neurofilament or anti-nNOS showed, for the first time, that immunoreactivity for the GLP1R was expressed in nitrergic neurons of the myenteric plexus. In conclusion, the results of this study suggest that GLP1R is expressed in the human colon and, once activated by exogenous GLP1, mediates an inhibitory effect on large intestine motility through NO neural release.

AB - Glucagon-like peptide 1 (GLP1) is a naturally occurring peptide secreted by intestinal L-cells. Though its primary function is to serve as an incretin, GLP1 reduces gastrointestinal motility. However, only a handful of animal studies have specifically evaluated the influence of GLP1 on colonic motility. Consequently, the aims of this study were to investigate the effects induced by exogenous GLP1, to analyze the mechanism of action, and to verify the presence of GLP1 receptors (GLP1Rs) in human colon circular muscular strips. Organ bath technique, RT-PCR, western blotting, and immunofluorescence were used. In human colon, exogenous GLP1 reduced, in a concentration-dependent manner, the amplitude of the spontaneous contractions without affecting the frequency and the resting basal tone. This inhibitory effect was significantly reduced by exendin (9-39), a GLP1R antagonist, which per se significantly increased the spontaneous mechanical activity. Moreover, it was abolished by tetrodotoxin, a neural blocker, or Nω-nitro-L-arginine - a blocker of neuronal nitric oxide synthase (nNOS). The biomolecular analysis revealed a genic and protein expression of the GLP1R in the human colon. The double-labeling experiments with anti-neurofilament or anti-nNOS showed, for the first time, that immunoreactivity for the GLP1R was expressed in nitrergic neurons of the myenteric plexus. In conclusion, the results of this study suggest that GLP1R is expressed in the human colon and, once activated by exogenous GLP1, mediates an inhibitory effect on large intestine motility through NO neural release.

KW - Colonic motility

KW - GLP-1 receptor expression

KW - Intestinal peptides

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84897902330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897902330&partnerID=8YFLogxK

U2 - 10.1530/JOE-13-0525

DO - 10.1530/JOE-13-0525

M3 - Article

C2 - 24443715

AN - SCOPUS:84897902330

VL - 221

SP - 29

EP - 37

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 1

ER -